TMEM199-CDG is a rare genetic disorder caused by a mutation in the TMEM199 gene. It is characterized by a variety of symptoms, including intellectual disability, seizures, and movement disorders. It is inherited in an autosomal recessive pattern, meaning that both copies of the gene must be mutated for a person to be affected by the disorder.

The symptoms of TMEM199-CDG vary from person to person, but can include:

-Developmental delays
-Growth delays
-Feeding difficulties
-Seizures
-Cognitive impairment
-Movement disorders
-Gastrointestinal problems
-Vision and hearing problems
-Heart defects
-Kidney problems
-Skin abnormalities
-Immune system problems

TMEM199-CDG is caused by mutations in the TMEM199 gene. These mutations lead to a deficiency in the protein encoded by the gene, which is involved in the formation of glycosylphosphatidylinositol (GPI)-anchored proteins. This deficiency can cause a variety of symptoms, including developmental delays, seizures, vision and hearing problems, and gastrointestinal issues.

Currently, there is no cure for TMEM199-CDG. Treatment focuses on managing the symptoms and complications of the condition. This may include physical therapy, occupational therapy, speech therapy, nutritional support, and medications to help manage seizures, gastrointestinal issues, and other symptoms. In some cases, surgery may be recommended to help manage certain complications.

The risk factors for TMEM199-CDG include:

1. Family history of the disorder
2. Mutation in the TMEM199 gene
3. Consanguinity (marriage between close relatives)
4. Advanced maternal age
5. Exposure to certain environmental toxins or medications during pregnancy.

At this time, there is no cure for TMEM199-CDG. However, there are medications that can help manage the symptoms of the disorder. These medications include anticonvulsants, anti-inflammatory drugs, and muscle relaxants. Additionally, physical and occupational therapy can help improve mobility and coordination.